The decreased Fndc5/irisin levels in COPD may impair skeletal muscle growth and developmental potential and weaken the antioxidative capacity, thereby promoting muscle atrophy and dysfunction. This evidence concerns the gene FNDC5 and chronic obstructive pulmonary disease.